The team ultimately found that the individuals who received a single twenty-five-milligram dose of COMP360 psilocybin experienced a significant reduction in depression scores only three weeks post-treatment.
There were still adverse side effects among the participants– including headaches, fatigue, nausea, dizziness, and suicidal ideation.
However, according to Professor Guy Goodwin, the Chief Medical Officer of COMPASS Pathways, the clinical trial’s success in helping normally treatment-resistant patients far outweighed the negatives.
“We saw positive results in a particularly difficult-to-treat group of patients, and the highest dose of COMP360 psilocybin had the greatest impact on people’s depression. This suggests that COMP360 psilocybin has a true pharmacological effect, a finding that is critical for it to be recognized as a new treatment option in the future,” Goodwin said.
So now, the team is eager to continue testing the efficacy of psilocybin among patients with TDR.
“Our task now is to investigate psilocybin for treatment-resistant depression in larger clinical trials with more participants, comparing it both to placebo and to established treatments,” explained Dr. James Rucker, one of the study’s researchers.
To read the study’s complete findings, which have since been published in The New England Journal of Medicine, visit the link here.
If true crime defines your free time, this is for you: join Chip Chick’s True Crime Tribe
Last Year, She Was Last Seen Walking Around Her Tiny Town, But Then She Disappeared